Sensitivities to various epidermal growth factor receptor‐tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor‐tyrosine kinase inhibitor?

Most patients with non‐small cell lung cancer (NSCLC) harboring common epidermal growth factor receptor (EGFR) mutations, such as deletions in exon 19 or the L858R mutation in exon 21, respond dramatically to EGFR tyrosine kinase inhibitors (EGFR‐TKI), and their sensitivities to various EGFR‐TKI hav...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Cancer Sci
Главные авторы: Banno, Eri, Togashi, Yosuke, Nakamura, Yu, Chiba, Masato, Kobayashi, Yoshihisa, Hayashi, Hidetoshi, Terashima, Masato, de Velasco, Marco A., Sakai, Kazuko, Fujita, Yoshihiko, Mitsudomi, Tetsuya, Nishio, Kazuto
Формат: Artigo
Язык:Inglês
Опубликовано: John Wiley and Sons Inc. 2016
Предметы:
Original Articles
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4982590/
https://ncbi.nlm.nih.gov/pubmed/27240419
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.12980
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы